Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y

Published 05/19/2016, 03:24 AM
Updated 07/09/2023, 06:31 AM

Merck (NYSE:MRK) KGaA MKGAF is a science and technology company in healthcare, life science and performance materials. Founded in 1668, it is the world's oldest pharmaceutical and chemical company.

The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.

The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.

The company lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer (NYSE:PFE).

The recent the acquisition of Sigma-Aldrich (NASDAQ:SIAL) led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300,000 products, thereby enabling it to customers all over the world.

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: The company’s first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5, compared to the year-ago figure of 70 cents.

Revenue: The company posted revenues of $4 billion in the reported quarter.

Key Stats: All three business units continued to perform well in the first quarter. The acquisition of Sigma-Aldrich boosted sales in the reported quarter. For 2016, the company expects net sales in the range of €14.8–€15 billion. Backed by the Sigma-Aldrich acquisition, the company expects a positive portfolio effect on sales in the low double-digit percentage range.

Check back later for our full write up on earnings report later!


Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.